Examples of clinical trials targeting CAFs

Strategy Approach Indications Combination Trial ID
CAF depletion Anti Nectin-4 and FAP CAR T cells Nectin4-positive advanced malignant solid tumors - NCT03932565
FAP-IL-2R (R06874281) Advanced or metastatic melanoma Anti-PD-1 NCT03875079
Unresectable advanced and/or metastatic renal cell carcinoma Anti-PD-L1 ± anti-VEGF NCT03063762
Metastatic pancreatic ductal adenocarcinoma Chemotherapy or anti-PD-L1 NCT03193190
Breast cancer Anti-Her2; anti-EGFR NCT02627274
FAP inhibitor (talabostat/BXCL701) Advanced solid cancers Anti-PD-1 NCT04171219
Suppression of CAF activation Vitamin D Cervical/uterine cancer Radiation or anti-PD-1 NCT03192059
Metastatic pancreatic ductal adenocarcinoma Chemotherapy or anti-PD-1 NCT02754726
Targeting CAF-effector molecules CXCR4 antagonist motixafortide (BL-8040) Metastatic pancreatic cancer Anti-PD-1 NCT02826486
CD73 blockade Advanced solid tumors Anti-PD-1 NCT02754141
Targeting CAF-induced ECM remodeling Pegylated recombinant hyaluronidase (PEGPH20) Pancreatic cancer Chemotherapy NCT01839487
Gastric, gastroesophageal, or esophageal cancer Chemotherapy or anti-PD-L1 NCT03281369

CAR: chimeric antigen-receptor; EGFR: EGF receptor